Home › Funds › Provident Investment Management, Inc. › VRTX

Provident Investment Management, Inc. position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Provident Investment Management, Inc. reported holding 131,577 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$68.8M, representing 6.89% of its reported portfolio and ranking #3 among its reported holdings. Provident Investment Management, Inc. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)131.58K sh
Reported value held$68.79M
Portfolio Weight6.89%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Provident Investment Management, Inc.'s VRTX position evolved

Provident Investment Management, Inc. first disclosed a stake in VRTX in Q3 2023 at 161,169 shares (US$56.0M). The position peaked in Q1 2025 at 156,325 shares, worth US$75.8M. Across 13 filings, Provident Investment Management, Inc. increased the stake 2 time(s), trimmed it 7 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 131,577 shares valued at US$68.8M — a reduction of -9,151 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 161.17K $56.04M New
Q4 2023 160.32K $65.23M Reduce
Q1 2024 160.12K $66.93M Hold
Q2 2024 159.86K $74.93M Hold
Q3 2024 155.50K $72.32M Reduce
Q4 2024 155.07K $62.45M Hold
Q1 2025 156.32K $75.79M Add
Q2 2025 158.71K $70.66M Add
Q3 2025 153.41K $60.08M Reduce
Q4 2025 149.26K $67.67M Reduce
Q1 2026 147.62K $65.92M Reduce
Q2 2026 140.73K $69.90M Reduce
Q3 2026 131.58K $68.79M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Provident Investment Management, Inc. held VRTX?

Provident Investment Management, Inc. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Provident Investment Management, Inc.'s current position in VRTX?

As of Q3 2026, Provident Investment Management, Inc. holds 131.58K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $68.79M, representing 6.89% of its reported portfolio and ranking #3.

Has Provident Investment Management, Inc. been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Provident Investment Management, Inc. reduced its position in VRTX. The position peaked in Q1 2025 at 156.32K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.